These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9839765)

  • 41. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
    Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S67-71. PubMed ID: 8793605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
    Smulders RA; Kuipers ME; Krauwinkel WJ
    Br J Clin Pharmacol; 2006 Aug; 62(2):210-7. PubMed ID: 16842396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers.
    Yi S; Kim JW; Kim TE; Kim J; Jun YK; Choi J; Yoon SH; Cho JY; Song SH; Shin SG; Jang IJ; Yu KS
    Int J Clin Pharmacol Ther; 2011 May; 49(5):321-7. PubMed ID: 21543035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin?
    Cohen E; Almog S; Staruvin D; Garty M
    Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
    Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin.
    Yan JH; Meyers D; Lee Z; Danis K; Neelakantham S; Majumdar T; Rebello S; Sunkara G; Chen J
    J Clin Pharmacol; 2014 Jul; 54(7):800-8. PubMed ID: 24619917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects.
    Ohnishi A; Mihara M; Kamakura H; Tomono Y; Hasegawa J; Yamazaki K; Morishita N; Tanaka T
    J Clin Pharmacol; 1993 Nov; 33(11):1086-91. PubMed ID: 8300891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
    Schwartz JI; De Smet M; Larson PJ; Verbesselt R; Ebel DL; Lins R; Lens S; Porras AG; Gertz BJ
    J Clin Pharmacol; 2001 Jan; 41(1):107-12. PubMed ID: 11144988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absence of a clinically relevant interaction between etanercept and digoxin.
    Zhou H; Parks V; Patat A; Le Coz F; Simcoe D; Korth-Bradley J
    J Clin Pharmacol; 2004 Nov; 44(11):1244-51. PubMed ID: 15496642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.
    Vaz da Silva M; Costa R; Soares E; Maia J; Falcão A; Almeida L; Soares da Silva P
    Fundam Clin Pharmacol; 2009 Aug; 23(4):509-14. PubMed ID: 19500154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pisa syndrome due to donepezil: pharmacokinetic interactions to blame?
    Pollock D; Cunningham E; McGuinness B; Passmore AP
    Age Ageing; 2017 May; 46(3):529-530. PubMed ID: 28104598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
    Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
    J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Absence of an interaction between tigecycline and digoxin in healthy men.
    Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
    Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
    Doody RS; Geldmacher DS; Gordon B; Perdomo CA; Pratt RD;
    Arch Neurol; 2001 Mar; 58(3):427-33. PubMed ID: 11255446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.
    Takeuchi R; Shinozaki K; Nakanishi T; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):68-74. PubMed ID: 26467765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Donepezil use in Alzheimer disease.
    Barner EL; Gray SL
    Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.
    Relkin NR; Reichman WE; Orazem J; McRae T
    Dement Geriatr Cogn Disord; 2003; 16(1):15-24. PubMed ID: 12714795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin.
    Soul-Lawton JH; Weatherley BC; Posner J; Layton G; Peck RW
    Br J Clin Pharmacol; 1998 Jan; 45(1):87-9. PubMed ID: 9489600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.